Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A. Zaccarelli M, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397546 Free PMC article.
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy.
Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, Orofino G, d'Ettorre G, Bai F, Celesia MB, Quiros Roldan E, Maserati R, Sterrantino G, Tommasi C, Boumis E, Iardino MR, Antinori A. Ammassari A, et al. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e113-5. doi: 10.1097/QAI.0b013e3182359d2a. J Acquir Immune Defic Syndr. 2011. PMID: 22033235 No abstract available.
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
State of the Art of Dual Therapy in 2015.
Nozza S, Svicher V, Saracino A, d'Ettorre G, De Luca A, Maggiolo F, Bonora S, di Biagio A, Rusconi S, Mussini C. Nozza S, et al. AIDS Rev. 2015 Jul-Sep;17(3):127-34. AIDS Rev. 2015. PMID: 26450801 Review.
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, Loiacono L, Ammassari A, Bellagamba R, Colafigli M, D'Ettorre G, Di Giambenedetto S, Antinori A, Zaccarelli M. Latini A, et al. BMC Infect Dis. 2016 Aug 11;16(1):401. doi: 10.1186/s12879-016-1703-z. BMC Infect Dis. 2016. PMID: 27515949 Free PMC article.
354 results